Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
The DOI matches its Crossref record; 220 of the 221 references it cites were found in a registry or an index.
Abstract
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but concerns [13] have remained about supersensitivity psychosis [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“In the era of first-generation antipsychotics (FGAs) both supersensitivity psychosis and tardive dyskinesia were widely studied [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Chouinard et al. [9] described withdrawal reactions due to antipsychotics dose decrease, discontinuation, or switch and concluded that acute withdrawal symptoms, rebound, and persistent post-withdrawal disorders may occur”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Social Origins of Depression: A Study of Psychiatric Disorder in Women.
Schnitzer, P. K., Brown, G. W., & Harris, T. (1980) · Contemporary Sociology · doi:10.2307/2065631 · Cited by 3,053
A permanent change in brain function resulting from daily electrical stimulation
Goddard, G. V., McIntyre, D. C., & Leech, C. K. (1969) · Experimental Neurology · doi:10.1016/0014-4886(69)90128-9 · Cited by 3,052
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Book Review: Measurement and Classification of Psychiatric Symptoms
Priest, R. G. (1975) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591577506800751 · Cited by 2,262
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Research works printed but not linked: 1
- 10.2165/1120086-000000000-00000 · doi:10.2165/1120086-000000000-00000
Cited by
Items 201–270 of 270
Morimoto, Y., Kanegae, S., & Ozawa, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_54-1 · Cited by 1
Olanzapine Reduction From High Dose to Standard Dose
Okeya, K., Misawa, F., 藤井, 康., & Takeuchi, H. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001459 · Cited by 1
“Long-term antipsychotic treatment can upregulate dopamine D2 receptors and induce DSP.(9) The characteristics of DSP include tolerance to antipsychotics; indeed, a study showed that the dose of long-acting injectable second-generation antipsychotics increased over 3 years in some patients with schizophrenia, which sug…”
BackgroundKanahara, N., Kimura, H., Kinoshita, T., Iyo, M., & Takekita, Y. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2023.21.1.197 · Cited by 1
“Tardive dyskinesia, is also an important sign of DSP [2,3].”
BackgroundSelf-citationMishra, B. R., Biswas, T., Sreeraj, V. S., Nath, S., Mohapatra, D., & Maiti, R. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15777 · Cited by 1
“Before switching to clozapine a changeover to a lower potency atypical antipsychotic of relatively longer half-life may be beneficial.(3,7) Reduction of antipsychotic dose helped to control the dystonic episodes along with the associated stress-induced psychotic symptoms.”
BackgroundInfluentialAntipsychotic Drugs: Do They Define Schizophrenia or Do They Blunt All Emotions?
Belmaker, R. H., & Lichtenberg, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-40371-2_6 · Cited by 1
The impact of fluphenazine withdrawal: a mirror-image study
Meehan, S., Moran, S., Rainford, A., McDonald, C., & Hallahan, B. P. (2024) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2024.2 · Cited by 1
“…withdrawal of dopamine antagonistic antipsychotics (i.e. FGAs), result in sensitised dopamine receptors exposed to physiological levels of dopamine (Chouinard et al., 2017), potentially leading to increased dopaminergic activity in pathways associated with psychosis including associative striatal…”
BackgroundTherapieresistente Schizophrenie
Wagner, E. M., & Hasan, A. (2024) · PSYCH up2date · doi:10.1055/a-2299-0927 · Cited by 1
Tardive Dyskinesia and Dopamine Oxidation, Cumulative Effects
Adams, J. D., Jr. (2019) · J — Multidisciplinary Scientific Journal · doi:10.3390/j2020011 · Cited by 1
“Patients suffering from tardive dyskinesia demonstrate abnormal brain imaging in the striatum [8], which is an area with abundant dopaminergic nerve terminals.”
BackgroundNew Applications of Well-Being Therapy
Benasi, G., Guidi, J., Rafanelli, C., & Fava, G. A. (2019) · RIVISTA SPERIMENTALE DI FRENIATRIA · doi:10.3280/rsf2019-001006 · Cited by 1
Mustafa, F. A., & Nayar, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4596 · Cited by 1
Dehanov, S., Ferreira, T., & Maia, T. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.133 · Cited by 1
Schölin, J. S., Cruz, J. R., & Hjorth, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1155395 · Cited by 1
Movement disorders in psychiatry as symptom, as side effect, and as risk factor
Willems, A. E. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231109aw · Cited by 2
Schizophrenia and Related Psychoses
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg001.pub2 · Cited by 2
Louie, K., Jauhar, S., Rubio, J. M., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · medRxiv · doi:10.64898/2026.01.19.26344378 · Cited by 1
Bowtell, M., Ratheesh, A., & O'Donoghue, B. N. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.006
Dopamine supersensitivity psychosis: Pharmacological mechanisms
Almeida, B. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.243
Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)
Gäebel, W., Hasan, A., & Falkai, P. (2019) · Springer eBooks · doi:10.1007/978-3-662-59380-6_5
Kaufmann, M., & Lehmann, P. (2019) · NeuroTransmitter · doi:10.1007/s15016-019-6915-1
The Impoverishment of Psychiatric Knowledge
Aftab, A., & Fava, G. A. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780192870322.003.0005
Servonnet, A., Allain, F., Gravel-Chouinard, A., Hernández, G., Caporuscio, C. B., Legrix, M., Lévesque, D., Rompré, P.-P., & Samaha, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.08.287664
Self-citationIntroduction à la classification des psychoses endogènes de Karl Leonhard
Foucher, J., Elowe, J., & Berna, F. S. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-77128-6.00018-8 · Cited by 2
Treating schizophrenia – Thinking beyond the choice of antipsychotic
Lugg, W. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211037242
“Chouinard recently proposed guidelines for the prevention of both TD and SP – the choice of antipsychotic formed but one of several recommendations (Chouinard et al., 2017).”
BackgroundIn kleinen Schritten reduzieren
Brandt, L., Montag, C., & Gutwinski, S. (2021) · NeuroTransmitter · doi:10.1007/s15016-021-9192-8
Case Presentation: Iatrogenic Psychosis
Fariba, K. (2021) · doi:10.53902/jpssr.2021.01.000522
Galani, V., Besson, M. J., Chytas, V., Hénaff, C. L., & Prada, P. (2022) · JMIG · doi:10.53738/revmed.2022.18.769.276
Continuous versus extended antipsychotic dosing in schizophrenia: Less is morePreprint
Servonnet, A., Uchida, H., & Samaha, A. (2020) · doi:10.31234/osf.io/q5kdm
Self-citationRole of asenapine as an augmenter for treatment-resistant schizophrenia
Jumaili, W. A., & Jain, S. B. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100019
Antipsychotic Induced Dopamine Receptor Supersensitivity and It’s Clinical Implications
Lazuardi, R., Rina, K., & Diana, D. (2022) · Jurnal Psikiatri Surabaya · doi:10.20473/jps.v11i1.27186
Takeuchi, H., & Watabe, K. (2022) · Research Square · doi:10.21203/rs.3.rs-2146246/v1
Morimoto, Y., Kanegae, S., & Ozawa, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_54 · Cited by 1
The challenge of managing difficult to treat psychiatric conditions
Serretti, A. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000460
Weinmann, S. (2023) · Psychiatrische Praxis · doi:10.1055/a-1952-1910
Breakthrough Psychosis and Long-Acting Injectable Antipsychotics
Joo, E.-J., Lee, K. Y., Jeong, S. H., & Kim, Y. S. (2023) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2023.26.1.1
Serious states induced by taking psychopharmacs and their treatment
Češková, E., & Horská, K. (2023) · Psychiatrie pro praxi · doi:10.36290/psy.2023.015
Amaral, D. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-08052023-105940
Pendidikan Dokter, F. K., Indrayani, T. A., Khoirunnisa, A., Pendidikan Dokter, F. K., Aviciena, A., & Pendidikan Dokter, F. K. (2023) · Khazanah Jurnal Mahasiswa · doi:10.20885/khazanah.vol15.iss2.art4
Fitzgerald, P. J. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00026
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
Uchida, H., Kim, E., Jarskog, L. F., Fleischhacker, W. W., Remington, G. J., & Lieberman, J. A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_134 · Cited by 1
Pisa syndrome induced by discontinuation of low dose sulpiride: a case reportPreprint
Koyama, G., Nakano, M., Takata, T., Mimura, Y., Uchida, H., & Funayama, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5315404/v1
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00003-9
Pearson, M., & Pringle, A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192864048.003.0019
Hamard, J., Montastruc, F., Boulefaa, D., et al. (2025) · Therapies · doi:10.1016/j.therap.2025.02.014
Ruiz‐Pérez, G., Krämer, U. M., Lippert, J., Ullrich, N., & von Peter, S. (2025) · Research Involvement and Engagement · doi:10.1186/s40900-025-00809-w
“None of the few existing studies on how to implement the involvement of various stakeholders in the context of a review study [4, 20, 21, 24, 29] focuses on an early, pre-protocol phase.”
Liu, C.-F., Yuan, J.-L., Cheng, J., Lu, J., Wang, W., Zhong, S., Lu, C.-H., Li, Q., Xu, Y., Zhou, L., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07707-1
Neuropsychiatric drug development in China: Current status and emerging trends
Huang, J., Huang, C., Ji, Y., Zhang, Q., Hu, S., Wei, Y., Hashimoto, K., Xu, X., & Yang, C. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03470-1
“Although some drugs can control certain symptoms, many patients experience relapses shortly after discontinuation [70].”
Biological aspects of drug resistance in schizophrenia
Tikhonov, D. V., & Kaleda, V. G. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612601119
Therapieresistente Schizophrenie
Wagner, E. M., & Hasan, A. (2026) · Nervenheilkunde · doi:10.1055/a-2764-5774
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v1
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v2
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v3
Masumo, Y., Kanahara, N., Otsuka, Y., Sudo, Y., Ishii, T., Sato, H., Idemoto, K., Komatsu, H., Fujita, Y., Oda, Y., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345078
Self-citationChu, R. S. T., Waltz, J. A., Gold, J. M., Wo, S. F., Wong, C. F., Hui, C. L. M., Chan, S. K. W., Lee, E. H. M., Lui, S. S. Y., Chen, E. Y. H., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112824 · Cited by 1
Shi, L., Wang, H., Xu, H., Yang, Y., Zhu, Y., & Zhao, Y. (2026) · Brain Disorders · doi:10.1016/j.dscb.2026.100316
Pruett, B. S., Johnston, C. H., & Burk, B. G. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551913.lg06
SwapIII: Clarifying the role of D2 receptor occupancy in psychosis and movement disorders
Shakir, M., van Harten, P. N., Hoogendoorn, A. W., Willems, A. E., Stout, T. L. L., & Tenback, D. E. (2026) · Psychiatry Research Communications · doi:10.1016/j.psycom.2026.100266
Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators
Hudnik, L. K., Kosmačin, I., Pjevac, M., Dolžan, V., & Bon, J. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03207-y
Expert Consensus on the Use of Lurasidone for Bipolar I Depression in Asian Patients
Sulaiman, A. H., Chui, M.-C. E., Kongsakon, R., Lee, J. P., Lin, C., Ng, B. Y., Tan, M. W. L., Ting, J. H., & Idris, M. H. M. (2026) · ALPHA PSYCHIATRY · doi:10.31083/ap49358
Ferreira, J. P. M., de Campos, L. A. V., & da Silva, L. J. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i7.8506
Ramírez‐Herrera, O., D’Espessailles, A., Burrone, M. S., & Santander, N. G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118266
Chakraborty, W., Anand, A., & Roy, K. K. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111846
Can Drugs Relieve the Societal Burden of Psychopathology?
Strayhorn, J. M., Chai, K. Y. Y., & Zhang‐James, Y. (2026) · SpringerBriefs in modern perspectives on disability research. · doi:10.1007/978-981-92-0922-4_4
Li, Y., Li, H., Peng, S., Chen, X., Yang, C., Tu, Y., Fan, Y., & Liu, N. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117348
The neuropsychopharmacology of treatment discontinuation
Kim, B. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02518-8 · Cited by 1
“Discontinuation studies should be scaled to each drug ’ s half-life, spanning days to weeks for acute rebound and months for durable adaptations [4, 15].”
McLean, M. R., Hanley, L., & Yoo, M. (2026) · Case Reports in Psychiatry · doi:10.1155/crps/4635562
“An additional explanatory mechanism is dopamine super-sensi-tivity psychosis (DSP), whereby chronic D2 receptor antagonism may result in compensatory receptor upregulation and paradoxical psychosis despite ongoing antipsychotic exposure [17, 18].”
Relapse or rebound: the case for personalisation in antipsychotic discontinuation
Krishnadas, R., & Smitha, C. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00270-1
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19366114
Jen, Y.-W., Hwang, T.-J., Chan, H.-Y., Hsieh, M. H., Liu, C.-C., Liu, C.-M., Hwu, H.-G., Kuo, C.-H., Lin, Y.-T., Chien, Y.-L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13278224
Metadata
- Authors
- Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M.
- Affiliations
- Hôpital Saint-Antoine (FR)
- McLean Hospital (US)
- Chiba University (JP)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 86
- Issue
- 4
- Pages
- 189-219
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2701376032
- Cited by
- 270
- References
- 221
- Citations by year
- 2026: 29 · 2025: 19 · 2024: 32 · 2023: 36 · 2022: 29 · 2021: 39 · 2020: 29 · 2019: 37 · 2018: 17 · 2017: 3
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K10266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine receptor supersensitivity, tardive dyskinesia, treatment-resistant schizophrenia, psychotic relapse, atypical antipsychotics, long-acting injectable antipsychotics, prolactin, drug-induced movement disorders
- MeSH terms
- Brain, Dopamine, Humans, Psychoses, Substance-Induced, Antipsychotic Agents, Receptors, Dopamine D2, Dopamine D2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.